Hetero-modification of TRAIL trimer for improved drug delivery and in vivo antitumor activities

Poor pharmacokinetics and resistance within some tumor cell lines have been the major obstacles during the preclinical or clinical application of TRAIL (tumor-necrosis-factor (TNF)-related apoptosis-inducing ligand). The half-life of TRAIL(114-281) (114 to 281 amino acids) was revealed to be no more...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Sci Rep
Autori principali: Pan, Li-Qiang, Zhao, Wen-Bin, Lai, Jun, Ding, Ding, Wei, Xiao-Yue, Li, Yang-Yang, Liu, Wen-Hui, Yang, Xiao-Yue, Xu, Ying-Chun, Chen, Shu-Qing
Natura: Artigo
Lingua:Inglês
Pubblicazione: Nature Publishing Group 2015
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4597189/
https://ncbi.nlm.nih.gov/pubmed/26445897
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/srep14872
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi